A vaccine development platform for Gram-negative pathogens with "group 2" capsules.

带有“2 组”胶囊的革兰氏阴性病原体疫苗开发平台。

• 批准号: 343457
• 负责人: Whitfield Christopher
• 金额: $ 44.83万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-03-01 至 2021-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=343457&lang=en
• 关键词: Capsular Polysaccharides; Capsules; Cell Surfaces; Glycobiology; Glycosyltransferases; Gram-Negative Bacterial Pathogens; Lipopolysaccharides; Polysaccharide Biosynthesis; Protein Glycosylation; Vaccine Development

Gram-negative bacteria are responsible for a wide range of community and hospital-acquired infections that result in significant morbidity and mortality. They are significant contributors to health care costs in Canada. Antibiotic-resistance is a major co

革兰氏阴性菌是导致显著发病率和死亡率的广泛的社区和医院获得性感染的原因。他们是加拿大医疗保健费用的重要贡献者。抗生素耐药性是一个主要的问题。